The Effect of Opioid-Free Anesthesia in TMJ Surgery

Ketamine

Brief Summary

This study aims is to evaluate the effect of opioid free total intravenous anesthesia on postoperative quality of recovery in patients undergoing oral and maxillofacial surgery (OMF) temporomandibular joint (TMJ) surgery.

Intervention / Treatment

  • Dexmedetomidine / Ketamine / Lidocaine (DRUG)
    Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics, as needed clinically. This includes administration of 5 mcg/kg/min of ketamine plus 0.5 - 1.0 µg/kg/hr of dexmedetomidine (Precedex) as a continuous infusion, started from induction to stop one hour before surgery is anticipated to end.

Condition or Disease

  • Temporomandibular Joint Disorders

Phase

  • Phase 2

    • Study Design

    Study type: INTERVENTIONAL
    Status: Recruiting
    Study results: No Results Available
    Age: 18 Years to 75 Years
    Enrollment: 60 (ESTIMATED)
    Allocation: Randomized
    Primary Purpose: Health Services Research

    Masking

    Clinical Trial Dates

    Start date: Jun 18, 2021 ACTUAL
    Primary Completion: Dec 31, 2022 ESTIMATED
    Completion Date: Jul 31, 2023 ESTIMATED
    Study First Posted: Jan 26, 2021 ACTUAL
    Last Updated: Jul 14, 2022

    Sponsors / Collaborators

    Lead Sponsor: Massachusetts General Hospital
    Responsible Party: N/A

    This study will enroll 60 patients undergoing TMJ surgery at Massachusetts General Hospital. Anesthetic care will be standardized according to current institutional standards of care. Intraoperative clinicians will not be blinded to group assignment. Patients will be randomized to one of two groups:

    * Group 1 - Opioid-free Anesthesia Patients: Patients who are not receiving opioids but the total intravenous anesthetic during surgery.
    * Group 2 - Standard Anesthesia Patients: Patients who undergo the standard of care and receive opioids as part of their anesthetic regimen.

    Both groups employ strategies that are routinely used as part of standard clinical practice for TMJ surgery. Patients will otherwise receive the institutional standards of care for their surgical procedure and perioperative care.

    Following intraoperative drug administration patients will be followed until discharge from the PACU to assess study endpoints while in the hospital. At the time of discharge from the PACU, members of the study team will ask the patient to compete a brief survey on their satisfaction with pain management.

    Patients in this study will be anticipated to be discharged the same day as the surgical procedure. At the time of hospital or PACU discharge, the patient will be provided with a Medication Diary. This will be used to record pain medication administration in the first 48 hours after surgery, as well as any pain or complication they might experience at home.

    Participant Groups

    • Patients in this arm will not receiving opioids but the total intravenous anesthetic during surgery. Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics.

    • Patients in this arm will undergo the standard of care and receive opioids as part of their anesthetic regimen.

    Eligibility Criteria

    Sex: All
    Minimum Age: 18
    Maximum Age: 75
    Age Groups: Adult / Older Adult
    Healthy Volunteers: Yes

    Inclusion Criteria:

    * Patients aged 18 to 75 (inclusive)
    * Scheduled for TMJ surgery (including both unilateral and bilateral procedures)
    * Planned arthroscopic surgical procedure
    * Preoperative plan to discharge the same day

    Exclusion Criteria:

    * Inability to provide written informed consent
    * Pregnant patients
    * Open TMJ Surgeries
    * Planned overnight admission
    * Mental status disorder or patient who are unable to communicate

    This clinical trial is recruiting

    Are you interested in participating in this trial or others? We'd love to help.

    Primary Outcomes

    • Pain will be measured using the eleven point (0 to 10) numeric rating scale. Pain scores will be recorded every 15 minutes until discharge from the post-anesthesia care unit (PACU) and at 12 and 24 hours postoperatively. Clinically documented pain scores will be recorded. Our primary outcome will be the worst documented pain score while in the PACU. Additional pain score time points will be evaluated as secondary endpoints.

    Secondary Outcomes

    • Intraoperative and postoperative opioid consumption in the first 12, 24 and 48 hours postoperatively will be evaluated.

    • Use, dosage and time to use of rescue analgesia in the PACU will be reported.

    • Self-report pain satisfaction will be assessed at the time of PACU discharge using the Revised American Pain Society Patient Outcome Questionnaire.

    • The incidence of ileus, nausea/vomiting, and pruritis will be reported.

    • Length of PACU and hospital stay will be reported.

    • The total dose of Percocet used at 24 and 48 hours after surgery will be reported.

    More Details

    NCT Number: NCT04724759
    Other IDs: 2020P003873
    Study URL: https://clinicaltrials.gov/study/NCT04724759
    Last updated: Sep 29, 2023